

APPENDIX C

ABSTRACT OF PROTOCOL

A study of patients with advanced cancer who have failed standard therapy will receive treatment with Interleukin-2, Interleukin-4 and tumor infiltrating lymphocytes (TIL). An aliquot of TIL cells will be exposed to retroviral vector containing supernatant for the purpose of marking a portion of the TIL cells. The genetically marked TIL cells will be infused with the population of TIL cells to serve as a "tracer" of the infused TIL cells. The marked TIL cells can be detected by the presence of the gene inserted by the retroviral vector. At various times after administration of the TIL to the patient, samples of blood, lymph nodes, and tumor will be obtained and tested for the presence of marked TIL. The gene marked TIL will be used to evaluate the survival and trafficking of the infused TIL. The information obtained by marking the TIL will hopefully provides clues on how to further improve therapy for other patients.